Vacunas contra el virus chikungunya: avances y perspectivas

Patricia  Langjahr; Pablo Sotelo

doi:10.18004/rpr/2023.09.02.71

Patricia Langjahr Universidad Nacional de Asunción, Facultad de Ciencias Químicas, Departamento de Biotecnología, Grupo de Inmunología e Inmunotecnología. San Lorenzo, Paraguay. https://orcid.org/0000-0001-9793-3373
Pablo Sotelo Universidad Nacional de Asunción, Facultad de Ciencias Químicas, Departamento de Biotecnología, Grupo de Virología. San Lorenzo, Paraguay. https://orcid.org/0000-0002-6473-2134

DOI: https://doi.org/10.18004/rpr/2023.09.02.71

Keywords: alphavirus, chikungunya virus (CHIKV)), vaccines, viral vaccines, chikungunya vaccine, vaccine development

Abstract

Chikungunya virus (CHIKV) is an alphavirus that causes an illness characterized mainly by fever and joint/muscle pain. Between 25-50% of infections present with chronic diseases that can last from months to years. The first outbreak of CHIKV in Paraguay occurred in 2015, with the last outbreak occurring in 2022/2023. Several vaccine candidates against CHIKV are in different stages of development, and even recently (November/2023), the first vaccine against CHIKV, called VLA1553 (Ixchiq), was approved. In addition, at least 30 vaccine candidates are available for preclinical and clinical trials. With the approval of the first vaccine against CHIKV and the possibility of others coming to the market soon, due to the advanced status of other vaccine candidates, a new scenario will open for this disease. The introduction of effective vaccines is expected to generate an important advance in the prevention of this disease, reducing acute cases and the chronic effects of viral infection. This review analyzes the progress of CHIKV vaccines and examines the epidemiological surveillance challenges posed by the introduction of these vaccines.

Downloads

Download data is not yet available.

References

(1) de Lima Cavalcanti TYV, Pereira MR, de Paula SO, Franca RF de O. A Review on Chikungunya Virus Epidemiology, Pathogenesis and Current Vaccine Development. Viruses. 2022;14(5):969.

(2) Doran C, Elsinga J, Fokkema A, Berenschot K, Gerstenbluth I, Duits A, et al. Long-term Chikungunya sequelae and quality of life 2.5 years post-acute disease in a prospective cohort in Curaçao. Vasconcelos PFC, editor. PLoS Negl Trop Dis. 2022; 16(3):e0010142.

(3) McHugh J. Long-term effects of chikungunya. Nat Rev Rheumatol. 2018; 14(2):62–62.

(4) Gräf T, Vazquez C, Giovanetti M, De Bruycker-Nogueira F, Fonseca V, Claro IM, et al. Epidemiologic history and genetic diversity origins of chikungunya and dengue viruses, paraguay. Emerg Infect Dis. 2021; 27(5):1393–404.

(5) Dirección de Vigilancia de la Salud P. Arbovirosis-resumen del situación epidemiológica semanal [Internet]. [cited 2022 Nov 25]. Available from: https://dgvs.mspbs.gov.py/page/#arbovirosis.html

(6) Torales M, Beeson A, Grau L, Galeano M, Ojeda A, Martinez B, et al. Notes from the Field: Chikungunya Outbreak — Paraguay, 2022–2023 . MMWR Morb Mortal Wkly Rep. 2023;72(23):636–8.

(7) Silva LA, Dermody TS. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies. J Clin Invest. 2017; 127(3):737–49.

(8) Giovanetti M, Vazquez C, Lima M, Castro E, Rojas A, de la Fuente AG, et al. Rapid Epidemic Expansion of Chikungunya Virus East/Central/ South African Lineage, Paraguay. Emerg Infect Dis. 2023; 29(9):1859–63.

(9) Cardozo F, Rojas A, Marquez SCM, Morel R, Bernal C, Galeano ME, et al. Chikungunya in paraguay during the first country wide outbreak new clade of ecsa-genotype harboring structural and non-structural protein mutations [Internet]. 2023. Available from: https://virological.org/t/chikungunya-in-paraguay-during-the-first-country-wide-outbreak-new-clade-of-ecsa-genotype-harboring-structural-and-non-structural-protein-mutations/933

(10) Schilte C, Staikovsky F, Couderc T, Madec Y, Carpentier F, Kassab S, et al. Chikungunya Virus-associated Long-term Arthralgia: A 36-month Prospective Longitudinal Study. Singh SK, editor. PLoS Negl Trop Dis. 2013; 7(3):e2137.

(11) Tanabe ISB, Tanabe ELL, Santos EC, Martins W V, Araújo IMTC, Cavalcante MCA, et al. Cellular and Molecular Immune Response to Chikungunya Virus Infection. Front Cell Infect Microbiol. 2018; 8(October):1–15.

(12) Bramhachari PV. Dynamics of Immune Activation in Viral Diseases. Springer Singapore; 2020. 9–41 p. Available from: http://link.springer.com/10.1007/978-981-15-1045-8

(13) Lum F-M, Couderc T, Chia B-S, Ong R-Y, Her Z, Chow A, et al. Antibody-mediated enhancement aggravates chikungunya virus infection and disease severity. Sci Rep. 2018; 8(1):1860.

(14) Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT. Chikungunya: a re-emerging virus. Lancet. 2012; 379(9816):662–71.

(15) Reyes-Sandoval A. 51 years in of Chikungunya clinical vaccine development: A historical perspective. Hum Vaccin Immunother. 2019; 15(10):2351–8.

(16) Lum F-M, Teo T-H, Lee WWL, Kam Y-W, Rénia L, Ng LFP. An Essential Role of Antibodies in the Control of Chikungunya Virus Infection. J Immunol. 2013; 190(12):6295–302.

(17) Voss JE, Vaney M-C, Duquerroy S, Vonrhein C, Girard-Blanc C, Crublet E, et al. Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature. 2010; 468(7324):709–12.

(18) Raju S, Adams LJ, Earnest JT, Warfield K, Vang L, Crowe JE, et al. A chikungunya virus-like particle vaccine induces broadly neutralizing and protective antibodies against alphaviruses in humans. Sci Transl Med. 2023; 15(696):eade8273.

(19) Kam Y-W, Pok K-Y, Eng KE, Tan L-K, Kaur S, Lee WWL, et al. Sero-Prevalence and Cross-Reactivity of Chikungunya Virus Specific Anti-E2EP3 Antibodies in Arbovirus-Infected Patients. Powers AM, editor. PLoS Negl Trop Dis. 2015; 9(1):e3445.

(20) Sumathy K, Ella KM. Genetic diversity of Chikungunya virus, India 2006-2010: evolutionary dynamics and serotype analyses. J Med Virol. 2012; 84(3):462–70.

(21) Sam I-C, Chan YF, Chan SY, Loong SK, Chin HK, Hooi PS, et al. Chikungunya virus of Asian and Central/East African genotypes in Malaysia. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2009; 46(2):180–3.

(22) Chua C, Sam I, Merits A, Chan Y. Antigenic Variation of East / Central / South African and Asian Chikungunya Virus Genotypes in Neutralization by Immune Sera. 2016; 10(8):e0004960.

(23) Milligan GN, Schnierle BS, McAuley AJ, Beasley DWC. Defining a correlate of protection for chikungunya virus vaccines. Vaccine. 2019; 37(50):7427–36.

(24) Wressnigg N, Hochreiter R, Zoihsl O, Fritzer A, Bézay N, Klingler A, et al. Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial. Lancet Infect Dis. 2020; 20(10):1193–203.

(25) Schneider M, Narciso-Abraham M, Hadl S, McMahon R, Toepfer S, Fuchs U, et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023; 401(10394):2138–47.

(26) Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate [Internet]. Available from: https://valneva.com/press-release/valneva-reports-positive-initial-phase-3-safety-data-in-adolescents-for-its-single-shot-chikungunya-vaccine-candidate/

(27) Montalvo Zurbia-Flores G, Reyes-Sandoval A, Kim YC. Chikungunya Virus: Priority Pathogen or Passing Trend? Vaccines. 2023; 11(3):568.

(28) Bennett SR, McCarty JM, Ramanathan R, Mendy J, Richardson JS, Smith J, et al. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial. Lancet Infect Dis. 2022; 22(9):1343–55.

Vaccines against chikungunya virus: advances and perspectives

Abstract

Downloads

References